PubMed Health⌕ Search

Biomedical subjects

Jan Reedijk

Publications and source records attributed to Jan Reedijk.

At least 37 records · Page 2Linked to original sources
PubMed2005

Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.

The dinuclear platinum complexes with aliphatic diamines [{cis-Pt(NH(3))(2)Cl}(2)(mu-H(2)N(CH(2))(6)NH(2))](NO(3))(2) (1,1/c,c) and [{trans-Pt(NH(3))(2)Cl}(2)(mu-H(2)N(CH(2))(4)NH(2))](NO(3))(2) (1,1/t,t), which are known to be highly active in vitro against several cancer cell lines, have been modified with a fluorogenic reporter (carboxyfluorescein diacetate, CFDA) and a hapten (dinitrophenyl, DNP). These labeled complexes have been designed for fluorescence microscopy investigation of cellular pathways of promising dinuclear platinum anticancer drugs and present the first example of labeling biologically active dinuclear platinum complexes with a fluorescent reporter. The modified compounds interact with a guanine model base similarly to the label-free parent complexes. The uptake of the complexes with a fluorescent label and the respective unlabeled complexes in the U2-OS human osteosarcoma cell line and its cisplatin-resistant derivative, U2-OS/Pt cell line has been investigated. Cellular processing of the CFDA- and DNP-modified dinuclear platinum complexes in U2-OS and U2-OS/Pt cells has been studied.

Antineoplastic Agents↗
PubMed2005

Proton NMR spectroscopy and magnetic properties of a solution-stable dicopper(II) complex bearing a single mu-hydroxo bridge.

The reaction of copper(II) perchlorate with the macrocyclic ligand [22]py4pz in the presence of base leads to formation of a dinuclear complex [Cu(2)([22]py4pz)(mu-OH)](ClO(4))(3)xH(2)O, in which two copper ions are bridged by a single mu-hydroxo bridge. Each copper ion is further surrounded by four nitrogen atoms of the ligand. The mu-hydroxo bridge mediates a strong antiferromagnetic coupling (2J = -691(35) cm(-1)) between the metal centers, leading to relatively sharp and well-resolved resonances in the (1)H NMR spectrum of the complex in solution. We herein report the crystal structure, the magnetic properties, and the full assignment of the hyperfine-shifted resonances in the NMR spectrum of the complex, as well as the determination of the exchange coupling constant in solution through temperature-dependent NMR studies.

Journal Article↗
PubMed2005

Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.

The biological activity of N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones (aminoalkyl is 2-aminoethyl, 3-aminoprop-1-yl and 4-aminobut-1-yl) and their dinuclear platinum complexes has been evaluated in the U2-OS human osteosarcoma cell line and its cisplatin-resistant U2-OS/Pt subline. All the compounds have been found to exhibit high cytotoxicity in the sensitive cell line, and to overcome cisplatin resistance in U2-OS/Pt cells. Cellular processing of N,N'-bis(2-aminoethyl)-1,4-diaminoanthraquinone and the respective dinuclear platinum complex in the sensitive and resistant U2-OS cells has been studied over time using digital fluorescence microscopy. Cellular processing of the compounds has been found to be similar in sensitive and resistant U2-OS cells, which is in agreement with the lack of cross-resistance in the U2-OS/Pt cell line. Both the platinum complex and the free ligand quickly enter the cell and accumulate in the nucleus. The platinum complex is excreted from the cell via the Golgi apparatus, while the weakly basic anthraquinone ligand accumulates in the Golgi complex, where it is taken up by lysosomes and then transported to the cell surface. The cellular distribution of the fluorescent anthraquinones and their dinuclear platinum complexes in the sensitive/resistant pair of U2-OS osteosarcoma cell lines is compared with the earlier studied cellular processing in the sensitive/resistant pair of A2780 ovarian carcinoma cell lines. In the A2780cisR cell line, the platinum complexes (and not the free ligands) are sequestered in lysosomes, which is not the case in A2780 sensitive cells. The differences in cellular distribution of the compounds in these two sensitive/resistant pairs of cell lines most likely result from different resistance profiles in A2780cisR and U2-OS/Pt cells. Lysosomes of A2780cisR cells are less acidic than lysosomes of A2780 sensitive cells, which is likely to be the cause of a defect in endocytosis. The disruption of normal endocytosis might facilitate sequestration of the platinum complexes in lysosomes, which partly confers the cross-resistance of these complexes with cisplatin in the A2780cisR cell line. In contrast, sequestration in acidic vesicles does not occur in U2-OS/Pt cells that do not exhibit enhanced lysosomal pH and which are likely to have normal endocytosis.

Anthraquinones↗
PubMed2005

Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl)[RuIICl2(NO+)(terpy)]Cl.

The complex cis-(Cl,Cl)-[RuCl2(terpy)(NO)]Cl (1) has been synthesized by the reaction of [RuCl3(H2O)2(NO)] with terpyridine (terpy) and characterized by various spectroscopic, analytical techniques and using electronic structure calculation (DFT) methods. The cytotoxic activity and the DNA-binding properties of have also been studied using biochemical techniques. The results establish unequivocally that corresponds to a so-called [RuNO]6 species, which readily releases the nitrosyl ligand upon irradiation with a mercury lamp in acetonitrile solution. DFT calculations provided a satisfactory description of structural, bonding, electronic and related properties of the new compound and throw light on the mechanism of the photo-induced NO release. Screening on A2780 (human ovarian carcinoma) cell lines showed significant cytotoxicity with an IC50 value of 0.49 microM. 31P and 23Na NMR spectroscopy along with electrophoretic mobility studies illustrated that complex primarily binds by coordination to DNA without any pi-interaction between the planar terpy ligand and the DNA bases, while weak electrostatic interactions could not be excluded. Studies on the inhibition of the restriction enzymes DraI and SmaI revealed that prefers the guanine and cytosine bases of DNA.

Antineoplastic Agents↗
PubMed2005

Ligands rock & roll: stepwise twisting of two cis-coordinated lopsided N-heterocycles in an octahedral bis(2-phenylazopyridine)-ruthenium(II) complex with seven atropisomers.

1H NMR data of alpha-[Ru(azpy)2(MeBim)2](PF6)2 (azpy=2-phenylazopyridine, MeBim=1-methylbenzimidazole), 2, revealed the presence of a total of seven atropisomers at -95 degrees C: three head-to-tail, HT, isomers (A, C, and D), and four head-to-head, HH, isomers which, due to the presence of an intrinsic C2 axis in the alpha-[Ru(azpy)2] moiety, are two sets of identical pairs (B/B and E/E). The NMR data of 2 represent a unique example of a coordination compound that shows a variable temperature (VT) behavior with more, well-defined steps of slow-to-fast exchange of its atropisomers. At 65 degrees C, all atropisomers are in fast exchange; on lowering the temperature the sharp signals first broaden (at room temperature) and consecutively split up into two sets of relatively sharp signals, in slow exchange, at about 0 degrees C (D, 40 %, and the coalesced signals of ABBCEE, 60 %). Upon further cooling, the set of peaks belonging to D remain sharp until the lowest recording temperatures. The signals of the other set of resonances, on the other hand, first broaden again and then separate into two sets of broad peaks (C/E/E and A) and one set of sharp peaks (B and B in fast exchange); on lowering the temperature even more, these signals broaden once again and finally, at -95 degrees C, are split up into a total of four sets of signal (A, B/B, C, and E/E). At low temperatures, ROESY experiments revealed that atropisomerization occurs through the synchronous rotation of both MeBim ligands in the interconversion of the two "identical" HH atropisomers B and B, as well as in the interconversion between C and E/E. The HH rotamers B/B furthermore exhibit a slow-to-fast exchange atropisomerization behavior that is observed independently from the other dynamic processes in this compound. The versatile cis bifunctional binding of the DNA model bases (MeBim ligands) in 2 parallels the observation of alpha-[Ru(azpy)2Cl2] which shows extraordinarly high cytotoxicity against tumor cell lines.

DNA↗
PubMed2005

Solid-phase synthesis, characterization and DNA binding properties of the first chloro(polypyridyl)ruthenium conjugated peptide complex.

A general method for the synthesis of chloro(polypyridyl)ruthenium conjugated peptide complexes via a solid-phase strategy is described. The method is applied to synthesize two positional isomers of the complex [Ru(terpy)(4-CO2H-4'-Mebpy-Gly-L-His-L-LysCONH2)Cl](PF6). Even though the separation of the isomers was only partially achieved chromatographically, the isomers were unambiguously assigned by NMR spectroscopy. The interactions of the complex [Ru(terpy)(4-CO2H-4'-Mebpy-Gly-L-His-L-LysCONH2)Cl](PF6) with CT-DNA and plasmid DNA, have been studied with various spectroscopic techniques, showing that (i) the complexes coordinatively bind to DNA preferring the bases guanine and cytosine over the bases thymine and adenine after hydrolysis of the coordinated chloride, (ii) electrostatic interactions between the complex cation and the polyanionic DNA chain assist this binding (iii) only in the case of one isomer the peptide does interact further with DNA as evidenced from 31P NMR spectroscopy, (iv) DNA unwinding occurs in all cases with high binding ratio (Ru/base) values (r > 0.3).

Animals↗
PubMed2005

Probing the potential of platinum(II) complexes for the inhibition of thiol-dependent enzymatic activity.

The synthesis and biological evaluation of platinum(II) amine complexes designed to act as inhibitors of the human cysteine protease cathepsin B, a thiol-dependent enzyme, is described. The complexes, composed of a cathepsin targeting ligand and a platinum(II) moiety with varying degrees of reactivity towards nucleophiles were characterized by physical-analytical methods and a proof of principle was illustrated in a model reaction. In biological tests for inhibitory activity against cathepsin B the presented compounds did not show significant inhibitory activity.

Cathepsin B↗
PubMed2005

Combinatorial discovery of new asymmetric cis platinum anticancer complexes is made possible with solid-phase synthetic methods.

To efficiently access asymmetric cis platinum (II) complexes for biological evaluation, a new solid-phase synthesis was designed. This synthesis was used for the preparation of a small library of platinum compounds. Several compounds from this library revealed promising activity during a cytotoxicity screen. Two active compounds were, therefore, synthesised on a larger scale and tested more extensively against a larger panel of cell-lines, confirming their high potential as antitumour compounds. The work presented illustrates how a combination of a new methodology and established techniques can speed up the search for platinum complexes with improved cytotoxic profiles compared to cisplatin.

Cisplatin↗
PubMed2004

Aggregation of [Cu(II)4] building blocks into [Cu(II)8] clusters or a [Cu(II)4]infinity chain through subtle chemical control.

Coordination complexes of the ligand H3L [1,3-bis(3-oxo-3-phenylpropionyl)-2-hydroxy-5-methylbenzene] with Cu(II) are reported. Clusters showing various nuclearities or modes of supramolecular organization have been prepared by slightly changing the reaction conditions and have been crystallographically characterized. The reaction of H3L with one equivalent of Cu(OAc)2 in DMF yields the dinuclear complex [Cu2(HL)2(dmf)2] (1). Reaction in MeOH of H3L with an increased amount of metal, in the form of Cu(NO3)2, and excess strong base (nBu4NOH) affords the cluster [Cu8(L)2(OMe)8(NO3)2] (2). Complex 2 is a dimer of two linear [Cu4] arrays bridged by methoxide ligands, where the polynucleating ligand is fully deprotonated. The [Cu4]2 clusters are linked to each other by NO3- bridges to form one-dimensional coordination polymers. The link between [Cu8] units and their relative spatial positioning can be modified by changing the anion of the Cu(II) salt, as demonstrated by the synthesis of the cluster polymers [Cu8(L)2(OMe)8Cl2] (3) and [Cu8(L)(OMe)7.86Br2.14] (4), where only NO3- has been replaced by Cl- or Br-, respectively. Similarly, when ClO4- is used, compound [Cu8(L)2(OMe)8(ClO4)2(MeOH)4] (5) can be isolated. It contains independent [Cu8] units. A slight change in the stoichiometry of the reaction leading to 2 affords the related complex catena-[Cu4(L)(OMe)3(NO3)2(H2O)0.36] (6). This polymer contains essentially the same [Cu4] moiety as 2, albeit organized in a completely different arrangement. Each [Cu4] unit in 6 is linked by OMe- ligands to two such equivalent groups to form an infinite chain. Magnetic susceptibility measurements reveal weak antiferromagnetic exchange between Cu(II) centers in 1 (J = -0.73 cm(-1)) and strong antiferromagnetic coupling within [Cu4] chains in 2, 5, and 6 (most negative J values of -113.8 and -177.3 cm(-1) for 2 and 6, respectively).

Benzene Derivatives↗
PubMed2004

Bio-mimicking galactose oxidase and hemocyanin, two dioxygen-processing copper proteins.

The modelling of the active sites of metalloproteins is one of the most challenging tasks in bio-inorganic chemistry. Copper proteins form part of this stimulating field of research as copper enzymes are mainly involved in oxidation bio-reactions. Thus, the understanding of the structure-function relationship of their active sites will allow the design of effective and environmental friendly oxidation catalysts. This perspective illustrates some outstanding structural and functional synthetic models of the active site of copper proteins, with special attention given to models of galactose oxidase and hemocyanin.

Animals↗
PubMed2004

An unusual open cubane structure in a mu(1,1)-azido- and alkoxo-bridged tetranuclear copper(II) complex, [Cu4L2(mu(1,1)-N3)2].5H2O (H3L = N,N'-(2-Hydroxylpropane-1,3-diyl)bis-salicylideneimine).

A new end-on (EO) azido-bridged tetranuclear copper(II) complex [Cu(4)L(2)(mu(1,1)-N(3))(2)].5H(2)O derived from the ligand H(3)L (N,N'-(2-hydroxylpropane-1,3-diyl)bis-salicylideneimine) has been synthesized. Its X-ray structure shows an unusual Cu(4)O(2)N(2) open cubane core in which four copper(II) atoms are connected two by two through two mu(1,1)-azido species and three by three through two alkoxo bridges. The magnetic susceptibility data is dominated by strong antiferromagnetic interactions associated with the alkoxides and weak ferromagnetic interactions arising from the azides, in agreement with magneto-structural correlations found in the literature relative to such bridges in Cu(II) complexes.

Journal Article↗
PubMed2004

Complexes of a novel multinucleating poly-beta-diketonate ligand.

The synthesis of the new polynucleating ligand 1,3-bis-(3-oxo-3-(2-hydroxyphenyl)-propionyl)-benzene (H4L) is reported along with the preparation, structure and properties of its dinuclear complexes [Cu(2)(H(2)L)(2)(py)(2)](1), [Ni(2)(H(2)L)(2)(py)(4)](2), [Mn(2)(H(2)L)(2)(dmf)(4)](3), [Co(2)(H(2)L)(2)(dmf)(4)](4) and [Co(2)(H(2)L)(2)(MeOH)(4)](5), respectively. In complexes 1 to 5, the polydentate ligand is in its bis-deprotonated form, chelating the metals through its [small beta]-diketonate moieties. Magnetic measurements show that the metals within these molecules are maintained almost mutually independent.

Journal Article↗
PubMed2004

The beta-glucuronyl-based prodrug strategy allows for its application on beta-glucuronyl-platinum conjugates.

The use of platinum drugs in antitumour therapy is well established. An important drawback of these chemotherapeutics is the lack of selectivity for tumour cells, usually resulting in severe toxic side effects. A glucuronyl-platinum conjugate was designed and synthesised to test the compatibility of platinum compounds with beta-glucuronidase-based prodrug therapy. Instantaneous cleavage of the beta-glucuronic bond in the glucuronyl-platinum conjugate was observed upon addition of beta-glucuronidase resulting in Pt(II)(dach)(4-hydroxybenzylmalonate) and glucuronic acid.

Glucuronidase↗